Veradermics, Inc — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Veradermics announced positive topline results from Phase 3 Study 304 and 12-month data from Phase 2/3 Study 302 for VDPHL01 (extended-release minoxidil) in male pattern hair loss, with efficacy endpoints met (36.4–43.9 hairs/cm² increase at 6–12 months, 55.7–89.1% visible improvement rates) and favorable safety profiles. Female Phase 2 Study 207 also showed positive results; Study 306 (female Phase 2/3) enrollment complete with topline data expected 1H27. Cash position of $798.4M as of September 30, 2026, is expected to fund operations through 2030 and multiple Phase 3 readouts. Q3 2026 net loss was $21.0M (vs. $20.1M in Q3 2025); R&D expenses decreased $2.0M YoY to $16.1M, while G&A expenses increased $10.5M to $12.7M, driven by commercial readiness costs and stock-based compensation.
Why this rating
Positive Phase 3 efficacy/safety data and strong cash runway ($798M = 97% of assets) materially de-risk lead program. Yet regulatory approval and commercialization remain uncertain; no commercial revenue yet. Event is significant but not business-changing until FDA approval.
Tradability signal
NO TRADE
No trade: positive news with only -0.2% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.10% over 4 hrs, n=202). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $144.65 ▼ 0.23% | at our read · unknown $144.99 | +10 min · unknown $147.00 ▲ 1.39% | +30 min · unknown $149.43 ▲ 3.06% | +1 hr · unknown $146.82 ▲ 1.26% | +4 hrs · unknown $148.58 ▲ 2.48% |
The stock had already moved +0.24% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.